wt1 126-134 peptide
Biologicalexperimental
Clinical trial activity
14 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2002 (NCT00153582)
Timeline
Indications
Studied for
- Carcinoma · Phase 2
- Fallopian Tubes · Phase 1
- Hamartoma · Phase 1
- Leukemia · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- recombinant wt1 antigen-specific cancer immunotherapeutic
- recwt1-a10
- wt1 126-134 peptide
- wt1 analog peptide
- wt1 and pr1 peptide
- wt1 peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02737787 | Phase 1 | Apr 1, 2016 | Cornell University |
| NCT02405338 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2015 | MediGene, University of Oslo |
| NCT01827137 | N/A | Apr 1, 2013 | Cornell University |
| NCT01819558 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2013 | Institut Paoli-Calmettes |
| NCT01513109 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2011 | Free University of Brussels |
| NCT01842139 | Phase 1 | Dec 1, 2011 | National Cancer Institute (NCI), University of Chicago |
| NCT01266083 | Phase 2 | Dec 1, 2010 | Cornell University |
| NCT00923910 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00672152 | Phase 1 | Jun 1, 2007 | Duke University |
| NCT00488592 | Phase 2 | Jun 1, 2007 | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
| NCT00433745 | Phase 2 | Feb 1, 2007 | National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
| NCT00270452 | Phase 1 | Dec 22, 2005 | National Heart, Lung, and Blood Institute (NHLBI) |
| NCT00153608 | Phase 2 | Apr 1, 2004 | Humboldt University |
| NCT00153582 | Phase 2 | Apr 1, 2002 | Humboldt University |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 3 | 3 | 3 | 2010 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 3 | 3 | 2 | 2005 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 1 | 2007 |
| Humboldt University | Academic/Hospital | 2 | 2 | 1 | 2002 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 2 | 2008 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Free University of Brussels | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Institut Paoli-Calmettes | Academic/Hospital | 1 | 1 | 1 | 2013 |
| MediGene | For profit | 1 | 1 | 1 | 2015 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Oslo | Academic/Hospital | 1 | 0 | 1 | 2015 |
11 organizations
Page 1 / 1